Autologous and allogeneic stem cell transplantation in Waldenstrom's macroglobulinemia: Review of the literature and future directions

Seminars in Oncology

Volumn 30, Issue 2, 2003, Pages 286-290

  Anagnostopoulos, Athanasios ^a   Aleman, Ana ^a   Giralt, Sergio ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUDARABINE; MELPHALAN; NUCLEOSIDE DERIVATIVE; THIOTEPA;

AGING; ALLOTRANSPLANTATION; BONE MARROW PURGING; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL DESTRUCTION; CLINICAL TRIAL; DRUG MEGADOSE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOMA; MORTALITY; MULTIPLE MYELOMA; PRIORITY JOURNAL; REVIEW; STEM CELL MOBILIZATION; TREATMENT CONTRAINDICATION; WALDENSTROEM MACROGLOBULINEMIA; WHOLE BODY RADIATION;

EID: 0037396125     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2003.50052     Document Type: Review

References (23)

1. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, et al: Waldenstrom's macroglobulinemia: Clinical features, complications, and management. J Clin Oncol 18:214-226, 2000
2. Gobbi PO, Bettini R, Montecucco C, et al: Study of prognosis in Waldenstrom's macroglobulinemia: A proposal for a simple binary classification with clinical and investigational utility. Blood 83:2939-2945, 1994
3. Facon T, Brouillard M, Duhamel A, et al: Prognostic factors in Waldenstrom's macroglobulinemia: A report of 167 cases. J Clin Oncol 11:1553-1558, 1993
4. Dimopoulos MA, Alexanian R: Waldenstrom's macroglobulinemia. Blood 83:1452-1459, 1994
5. Dhodapkar MV, Jacobson JL, Gertz MA, et al: Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: Results of United States intergroup trial (Southwest Oncology Group S9003). Blood 98:41-48, 2001
6. Anagnostopoulos A, Giralt S: Stem cell transplantation (SCT) for Waldenstrom's macroglobulinemia (WM). Bone Marrow Transplant 29:943-947, 2002
7. Mustafa M, Powles R, Treleaven J, et al: Total therapy with VAMP/CVAMP + high dose melphalan and autograft for IgM lymphoplasmacytoid disease. Blood 92:281b, 1998 (suppl 1, abstr)
8. Desikan R, Dhodapkar M, Siegel D, et al: High-dose therapy with autologous haemopoietic stem cell support for Waldenstrom's macroglobulinaemia. Br J Haematol 105:993-996, 1999
9. Dreger P, Glass B, Kuse R, et al: Myeloablative radiochemotherapy followed by reinfusion of purged autologous stem cells for Waldenstrom's macroglobulinaemia. Br J Haematol 106:115-118, 1999
10. Yang L, Wen B, Li H, et al: Autologous peripheral blood stem cell transplantation for Waldenstrom's macroglobulinemia. Bone Marrow Transplant 24:929-930, 1999
11. Mazza P, Palazzo G, Amurri B, et al: Analysis of feasibility of myeloablative therapy and autologous peripheral stem cell (PBSC) transplantation in the elderly: An interim report. Bone Marrow Transplant 23:1273-1278, 1999
12. Anagnostopoulos A, Dimopoulos MA, Aleman A, et al: High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia, Bone Marrow Transplant 27:1027-1029, 2001
13. Ketterer N, Salles G, Moullet I, et al: Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 103:235-242, 1998
14. Visani G, Lemoli RM, Tosi P, et al: Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients. Br J Haematol 105:775-779, 1999
15. Michallet M, Thiebaut A, Dreger P, et al: Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): A report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias Working Party (CLWP). Br J Haematol 108:595-601, 2000
16. Sirohi B, Powles R, Treleaven J, et al: The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant 25:533-539, 2000
17. Attal M, Harousseau JL, Stoppa AM, et al: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335:91-97, 1996
18. Ueda T, Hatanaka K, Kosugi S, et al: Successful nonmyeloablative allogeneic peripheral blood stem cell transplantation (PBSCT) for Waldenstrom's macroglobulinemia with severe pancytopenia. Bone Marrow Transplant 28:609-611, 2001
19. Martino R, Shah A, Romero P, et al: Allogeneic bone marrow transplantation for advanced Waldenstrom's macroglobulinemia. Bone Marrow Transplant 23:747-749, 1999
20. Freedman AS, Neuberg D, Mauch P, et al: Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 94:3325-3333, 1999
21. van Besien KW, Mehra RC, Giralt SA, et al: Allogeneic bone marrow transplantation for poor-prognosis lymphoma: Response, toxicity and survival depend on disease histology. Am J Med 100:299-307, 1996
22. Khouri IF, Keating M, Körbling M, et al: Transplantlite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 16:2817-2824, 1998
23. Bjorkstrand BB, Ljungman P, Svensson H, et al: Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A retrospective casematched study from the European Group for Blood and Marrow Transplantation. Blood 88:4711-4718, 1996